Supernus Pharmaceuticals (SUPN) reported $207.71 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 38.6%. EPS of $0.59 for the same period compares to $0.42 a year ago.
The reported revenue represents a surprise of +10.22% over the Zacks Consensus Estimate of $188.45 million. With the consensus EPS estimate being $0.28, the EPS surprise was +110.71%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Supernus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Net product sales- Trokendi XR: $9.48 million versus the two-analyst average estimate of $6.35 million. The reported number represents a year-over-year change of -26%. Revenues- Net product sales- Oxtellar XR: $7.42 million versus $5.93 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -27.2% change. Revenues- Net product sales- APOKYN: $7.73 million compared to the $9.19 million average estimate based on two analysts. The reported number represents a change of -48.5% year over year. Revenues- Net product sales- Qelbree: $77.84 million versus the two-analyst average estimate of $80.06 million. The reported number represents a year-over-year change of +20.3%. Revenues- Collaboration revenue (ZURZUVAE): $27.64 million versus the two-analyst average estimate of $31.33 million. Revenues- Net product sales: $150.75 million compared to the $152.45 million average estimate based on two analysts. The reported number represents a change of +6.2% year over year. Revenues- Royalty, licensing and other revenues: $29.31 million versus the two-analyst average estimate of $2.5 million. The reported number represents a year-over-year change of +274%. Revenues- Net Product Sales- ONAPGO: $8.38 million compared to the $10.26 million average estimate based on two analysts. Revenues- Net product sales- GOCOVRI: $35.24 million compared to the $35.3 million average estimate based on two analysts. The reported number represents a change of +14.8% year over year.View all Key Company Metrics for Supernus here>>>
Shares of Supernus have returned -3.8% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).